Terbutaline aerosol from a metered dose inhaler via a 750 ml spacer

Dorow, P; Hidinger, K.-G.

doi:10.1007/bf00609623

Cited by 8 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an outpatient study of patients with COPD, Pauwels et al 131 compared the use of an MDI and that of an MDI with a valved holding chamber following the inhalation of terbutaline, and reported that the MDI with holding chamber may be more effective than MDI alone. In an outpatient study of patients with asthma or COPD, Dorow and Hidinger et al 132 reported no differences between the use of an MDI and that of MDI with a valved holding chamber.…”

Section: ␤ 2 -Agonists and Anticholinergic Agents For Copdmentioning

confidence: 98%

Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines

Dolovich

Ahrens

Hess

et al. 2005

Chest

678

419

View full text Add to dashboard Cite

Section: ␤ 2 -Agonists and Anticholinergic Agents For Copdmentioning

confidence: 98%

Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines

Dolovich

Ahrens

Hess

et al. 2005

Chest

678

419

View full text Add to dashboard Cite

“…In two studies in children [9,10], the spacer produced significantly better re sults than an ordinary pressurized aerosol. In adults better results were obtained for parameters in small airways [7], Also, Lindgren et al [8] reported significantly better results with a spacer.…”

Section: Discussionmentioning

confidence: 87%

Terbutaline Aerosol from a Metered Dose Inhaler with a 750-ml Spacer or as a Nebulized Solution

Stauder¹,

Hidinger²

1983

Respiration

View full text Add to dashboard Cite

The clinical effect of 1.0 mg terbutaline given as a pressurized aerosol with a 750-ml spacer was compared with that of 4.0 mg terbutaline given as a nebulized solution (Pari Inhalier Boy). No differences were found in the parameters measured – forced vital capacity, 1 s forced expiratory volume, forced mid-expiratory flow, and oscillatory resistance. The results indicate that the same clinical response to a given dose of a pressurized aerosol supplied with a 750-ml spacer has the same effect as a fourfold dose via a nebulizer. It is concluded that the more practical 750-ml spacer should be tried when contemplating nebulization therapy.

show abstract

The potential value of a 750‐ml spacer for the administration of inhaled corticosteroids to children

Reiser

Frame

Warner

1986

Pediatric Pulmonology

View full text Add to dashboard Cite

An open, cross-over trial was conducted on 25 asthmatic children, aged 6-13 years, who required inhaled steroids. They inhaled Budesonide 200 micrograms twice daily, either directly from the metered dose inhaler or via the pear spacer (PS), for 2 months on each, in randomized order. The effects of the treatment were monitored with diary cards recording peak expiratory flow rates twice daily, symptoms and treatment taken, and with monthly clinical assessments including more sensitive lung function studies (flow-volume loops and single breath nitrogen wash-out tests). There was no specifically PS-related improvement in symptoms or in the majority of tests, but the results showed improvement with time when using either method. The improvement was more distinct in some tests reflecting proximal airway calibre (i.e., PEFR) than in tests thought to reflect predominantly peripheral airway calibre (i.e., F50, RV). The bronchodilator responsiveness, as shown by the increase in lung function tests after a beta-agonist was given, was significantly greater for FVC during the periods when the PS was used, although there was no significant improvement in FEV2 or PEFR. The improvement in tests reflecting proximal airways may have been due to optimization of the inhalation technique, greater understanding of asthma, or better compliance with medication associated with regular attendance for the study. The greater bronchodilator response whilst children were inhaling budesonide by the PS may have been due to increased deposition or better distribution of the steroid but was probably related to a difference between the two groups in initial baseline function tests.

show abstract

Terbutaline aerosol from a metered dose inhaler via a 750 ml spacer

Cited by 8 publications

References 12 publications

Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines

Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines

Terbutaline Aerosol from a Metered Dose Inhaler with a 750-ml Spacer or as a Nebulized Solution

The potential value of a 750‐ml spacer for the administration of inhaled corticosteroids to children

Contact Info

Product

Resources

About